Conclusion
bleeding, sICH, cardio-embolism, cardioembolic stroke
SECONDARY, BLEEDING
The secondary analysis conducted in the RESCUE BT trial, with a specific focus on the cardio-embolism subgroup, has provided concerning insights into the concomitant administration of tirofiban and EVT. Our analysis has revealed a significant association between tirofiban usage and an increased risk of sICH among patients with cardioembolic stroke. These findings emphasize the potential harm and heightened bleeding risk associated with tirofiban administration in this population. To confirm and further explore these observations, additional studies are warranted, aiming to validate these findings and investigate alternative strategies for optimizing outcomes in patients with cardioembolic stroke.